The idea of @entity1091 's specificity for @entity162 was proposed in Cade's original work in 1949. Since then, many controlled studies have been performed, examining @entity1091 for treatment of @entity162 and other @entity146 conditions. This review was undertaken to determine if the suggestion of @entity1091 's specificity has support in the controlled studies conducted after Cade's initial proposal. Studies were selected in a Medline search, dating back to 1966 and also identified from the bibliography of some of these papers. The controlled trials with @entity1091 for the treatment of @entity162 and @entity162 , @entity308 , @entity161 , @entity914 were reviewed. The published studies with @entity1091 in other @entity146 were also considered. Additionally, we reviewed literature on other therapeutic agents proposed for @entity162 , looking at their comparative effectiveness to @entity1091 . The data analyzed give strong support for @entity1091 's being most effective in @entity162 , with minimal or no therapeutic effects in other @entity146 . The neurochemical underpinnings of this specificity are being investigated, without conclusive findings to date. The study of this paradigm of specificity in neuropsychopharmacology research may lead to meaningful contributions to understanding the pathophysiology of @entity162 and may help to develop newer treatments for this condition.

The XXXX ion: a foundation for psychopharmacological specificity.

@entity162 :: ('MESH:D001714', 'Disease') :: ['bipolar depression', 'bipolar disorder', 'mania'] @entity308 :: ('MESH:D003866', 'Disease') :: ['unipolar depression'] @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric', 'neuropsychiatric disorders', 'neuropsychiatric conditions'] @entity914 :: ('MESH:D011618', 'Disease') :: ['and schizoaffective disorder'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia'] @entity1091 :: ('MESH:D008094', 'Chemical') :: ['lithium']
@entity1091 :: (MESH:D008094,Chemical) :: ['lithium']
